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IDENTIFIKASI PEPTIDA MELEKAT RESEPTOR PENGAUT CD36 
MENGGUNAKAN PAPARAN FAJ M13 PEPTIDA 12-MER 
 
ABSTRAK 
 
 Reseptor pengaut CD36 tergolong dalam keluarga reseptor pengaut kelas B 
dan terlibat secara langsung dalam pengambilan lipoprotein teroksida. Pengumpulan 
lipid menyumbang kepada pembentukan sel busa, yang merupakan pencetus kepada 
plak aterosklerosis. Kajian ini bertujuan untuk mengenal pasti peptida faj CD36 kerana 
ia berpotensi untuk dibangunkan sebagai peptida perencat dan digunakan sebagai 
kaedah molekul untuk merawat masalah radang aterosklerosis. Dalam kajian ini, Ph.D-
12TM Phage Display Peptide Library yang telah disahkan melalui pemilihan faj 
streptavidin, kemudiannya digunakan dalam pemilihan terhadap CD36. Ujian 
kebolehan mengikat CD36 dijalankan dengan menginkubasi klon faj yang telah dipilih 
dengan dua jenis sel yang mengekspres CD36, sel CHO-CD36 dan U937 dan satu jenis 
sel tanpa pengekspresan CD36, sel HeLa, diikuti dengan pelabelan dengan antibodi 
anti-faj M13-PE dan isotaip IgG2b-PE. Semua sel tersebut dianalisis menggunakan 
mesin flow cytometer BD FACS CaliburTM dan data yang diperoleh dianalisis 
menggunakan perisian FLOWJO 7.6.5. Ujian spesifikasi ikatan dijalankan 
menggunakan ELISA berasaskan sel. Klon faj diinkubasi dengan sel dan dilabel 
dengan antibodi anti-faj M13-HRP. TMB digunakan dalam pengesanan faj dan isyarat 
dibaca menggunakan pembaca mikroplat. Struktur sekunder faj CD36 dan interaksi 
peptida terhadap reseptor CD36 masing-masing diramalkan menggunakan perisian I-
TASSER dan CABS-dock. Menerusi kajian ini, peptida faj dengan motif streptavidin, 
HPM, telah dipilih melalui pemilihan streptavidin, seterusnya mengesahkan kit yang 
telah digunakan. Pemilihan peptida CD36 menghasilkan klon faj tanpa sebarang motif 
 xv 
  
yang sama dengan motif peptida yang pernah diterbitkan apabila dianalisis 
menggunakan pangkalan data atas talian Target Unrelated Peptide Scanner 
(SAROTUP) dan Mimotope Database and Beyond (MimoDB). Analisis flow 
cytometry bagi ujian kebolehan mengikat menunjukkan 4 klon: klon B10, B14, B16 
dan B7 mempunyai kebolehan mengikat yang lebih tinggi terhadap sel CHO-CD36 
berbanding klon kawalan. Manakala, 3 klon: klon A15, B17 dan B22 mempunyai 
kebolehan mengikat yang lebih tinggi terhadap sel CHO-CD36 dan U937 berbanding 
klon kawalan. Ujian spesifikasi ikatan menggunakan ELISA menunjukkan klon B22 
lebih spesifik terhadap sel CHO-CD36 berbanding klon kawalan. Analisis interaksi 
menunjukkan klon B22 berinteraksi dengan reseptor CD36 melalui 3 bahagian 
interaksi putatif yang utama pada reseptor. Kesimpulannya, peptida faj CD36 yang 
spesifik berjaya dikenal pasti dengan menggunakan teknik pemilihan paparan faj. 
Peptida faj CD36, klon B22 mempunyai keupayaan mengikat dengan spesifikasi yang 
tinggi terhadap sel CHO-CD36 berbanding klon kawalan. Lebih menarik lagi, B22 
mengikat reseptor CD36 di satu tapak yang tidak pernah dilaporkan sebelum ini. 
Interaksi antara B22 dan CD36 yang novel ini menjadi satu pengetahuan asas untuk 
kajian di masa hadapan dalam menetukan rawatan yang berpotensi untuk radang 
atherosclerosis.  
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IDENTIFICATION OF A CD36 SCAVENGER RECEPTOR BINDING 
PEPTIDE USING A 12-MER PEPTIDE M13 PHAGE DISPLAY LIBRARY 
 
ABSTRACT 
 
CD36 is a class B scavenger receptor which is involved significantly in the 
uptake of oxidised low-density lipoprotein (oxLDL). Accumulation of lipid 
contributes to foam cells formation, which is the precursor to atherosclerosis plaque. 
The aim of this study was to identify specific peptides which interact and bind to CD36 
as it has the potential to be developed into a peptide inhibitor and as a molecular 
intervention in treating athero-inflammatory disorders. In this study, 12-mer Ph.D-
12TM Phage Display Peptide Library, which was validated in streptavidin panning, was 
used in selection against CD36. CD36-binding assay was performed by incubating the 
selected phages with two CD36-expressing cell lines, CHO-CD36 and U937 and a 
CD36-non expressing cell line, HeLa, followed by anti-M13 phage-PE and mouse 
IgG2b-PE isotype antibodies staining. All stained cells were acquired on BD FACS 
CaliburTM flow cytometer and analysed using FlowJo 7.6.5 software. Binding 
specificity was assayed using cell-based ELISA. The phage clones were incubated 
with the cells and stained with anti-M13-HRP. TMB was used in phage detection and 
the signal was read using a microplate reader. Secondary structure of CD36 phage and 
binding interaction of the peptide to CD36 receptor were predicted using I-TASSER 
and CABS-dock software, respectively. Phage bearing specific streptavidin motif, 
HPM, was selected from streptavidin panning and validated the library used in the 
selection. Fourth round of CD36 panning yielded unique phage clones that had no 
common motif with any published peptide when analysed using online database Target 
 xvii 
  
Unrelated Peptide Scanner (SAROTUP) and Mimotope Database and Beyond 
(MimoDB). Flow cytometric analysis of phage binding assay showed four clones: 
clones B10, B14, B16 and B7 had higher binding ability toward CHO-CD36 cells 
compared to the control clone. In addition, three other clones: clone A15, B17 and B22 
had greater binding ability towards CHO-CD36 and U937 cells compared to the 
control clone. ELISA binding specificity test showed that clone B22 had higher 
specificity towards CHO-CD36 cells compared to the control clone.  Docking analysis 
showed B22 interacted with CD36 receptor through three putative major contacts on 
the receptor binding sites. In conclusion, specific CD36 peptide phage was 
successfully identified by using phage display selection technique. The CD36 phage, 
B22 had higher binding ability and specificity towards CHO-CD36 cells compared to 
the control clone. More interestingly, B22 binds to CD36 receptor at a site which had 
not been reported before. This novel interaction between B22 and CD36 serves as a 
basis for future experiments in identifying a potential intervention and treatment for 
athero-inflammatory disorders.  
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CHAPTER 1 
1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Research overview 
 CD36 is a multi-ligand scavenger receptor which is expressed in various types 
of cells such as endothelial, adipocytes, epithelial, platelets, monocytes and 
macrophages. The receptor is responsible for several physiological processes 
including phagocytosis of apoptotic cells and microbial pathogens. It also plays a 
major role in pathological processes including angiogenesis, inflammation and 
atherosclerosis. CD36 binds to several ligands including Plasmodium falciparum 
malaria infected erythrocytes, long chain fatty acids and oxidised low density 
lipoprotein (oxLDL). 
 CD36 is able to bind oxLDL and causes the internalisation and uptake of 
oxLDL into macrophages. This reaction activates the transcription factor peroxisome 
proliferator-activated receptor gamma (PPARγ) which facilitates further uptake of 
oxLDL and enlarges pools of oxLDL. The interaction between CD36 and oxLDL 
induces secretion of pro-inflammatory cytokines and causes more immune cell 
infiltration in the arterial intima. Severe inflammation induces arterial narrowing or 
atherosclerosis, which result in cardiovascular disease (CVD) such as coronary heart 
disease. Therefore, manipulation of CD36 receptor is crucial in atherosclerosis 
intervention.  
 Identification of specific CD36 molecules using phage display selection offers 
new approach in treating atherosclerosis. Specific CD36 peptide can be developed into 
a peptide inhibitor that blocks the binding sites of oxLDL on the CD36 receptor. This 
in turn will prevent the oxLDL internalisation into macrophages, inhibit foam cells 
formation and reduce the risks of atherosclerosis. 
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1.2 What is scavenger receptor CD36? 
CD36 receptor was first isolated and characterised from the platelet membrane 
(Tandon et al., 1989b) and was originally known as platelet integral membrane 
glycoprotein IV (Tandon et al., 1989a; Pepino et al., 2014), an adhesion receptor for 
thrombospondin-1 (TSP-1) (Dawson et al., 1997; Silverstein and Febbraio, 2009). 
Recently, CD36 was classified as scavenger receptor-B2 (SR-B2) (Prabhudas et al., 
2014). CD36 is expressed in various cell types including macrophages and monocytes, 
adipocytes, platelet, epithelial cells in the kidney, cardiac myocytes (Febbraio et al., 
2001), microvasculature endothelial (Swerlick et al., 1992) and smooth muscle cells 
(Matsumoto et al., 2000).   
CD36 is involved in many physiological processes including clearance of 
apoptotic cells (Ferracini et al., 2013), phagocytosis of microbial pathogens (Baranova 
et al., 2008) and viral infection (Cooper et al., 2016), uptake of long chain fatty acids 
(Koonen et al., 2005) as well as regulation of angiogenesis (Osz et al., 2014). CD36 is 
also involved in several pathological process such as inflammation (Erdman et al., 
2009), pathogenesis of malaria (Gowda et al., 2013), pathogenesis of metabolic 
disorder such as diabetes and obesity (Kennedy and Kashyap, 2011), atherosclerosis 
(Park, 2014) and thrombosis (Nergiz-Unal et al., 2011).  
CD36 is a multi-ligand receptor which binds to several ligands including 
oxLDL (Endemann et al., 1993), long chain fatty acids (Nicholson et al., 1995), 
anionic phospholipids (Ryeom et al., 1996), apoptotic cells (Ren et al., 1995), 
Advanced Glycation End (AGE) product (Ohgami et al., 2001) and growth hormone 
releasing peptide (GHRPs), Hexarelin (Demers et al., 2004). It also serves as an 
adhesion receptor for collagen (Leung et al., 1992) and plasmodium falciparum 
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malaria infected erythrocytes (Febbraio et al., 1999) and shed photoreceptor outer 
segments (Savill et al., 1992).  
1.2.1 Molecular structure of CD36 
Human CD36 gene is located on chromosome 7 at q11.2 locus (Fernandez-
Ruiz et al., 1993). There are 15 exons in CD36 gene, however, exons 1, 2 and 15 are 
non-coding. N-terminal and C-terminal domains are encoded by exons 3 and 14 
(Armesilla and Vega, 1994). As shown in Figure 1.1, 5’-untranslated regions (5’-UTR) 
consists of exons 1a, 1b, 1c, 1e, 1f, 2 and part of exons 3 while the remaining segment 
of exon 14 and exon 15 make up the 3’-untranslated region (3-UTR) (Armesilla and 
Vega, 1994; Rac et al., 2007).  
CD36 receptor contains one short intracellular domain at both N- and C- 
terminal, two trans-membrane domains and one large extracellular domain (Rac et al., 
2007). The extracellular region which is rich in N-linked glycosylation sites and bears 
a hydrophobic domains (184-204) could potentially interact with the plasma 
membrane, a proline rich region (242-333) (Greenwalt et al., 1992; Lauzier et al., 
2011).  
Several binding site specific for CD36 ligands are located at the extracellular 
domain. Each of these ligands bind to CD36 receptor at specific domains, as shown in 
Figure 1.2. Domain 28-93 and 120-155 are responsible for binding to oxLDL (Puente 
Navazo et al., 1996; Pearce et al., 1998). Domain 155-183 is responsible for growth 
GHRPs, hexarelin (Navazo et al., 1996) and AGE (Ohgami et al., 2001). Domain 93-
120 is responsible for TSP-1 and -2 (Frieda et al., 1995; Yamashita et al., 2007).  
Domains 155-183 and 120-155 which are referred as CLESH (CD36 LIMP-II 
Emp sequence homology) are implicated in binding and endocytosis of apoptotic 
neutrophils (Navazo et al., 1996). This endocytosis happens in the present of integrin 
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complex αvβ3 and the CD36 ligand, TSP (Savill et al., 1992; Yamashita et al., 2007). 
In addition to that, two domains, domain 146-164 or 145-171 mediate the binding to 
P. falciparum erythrocytes membrane protein-1, which is specifically expressed by P 
falciparum infected erythrocytes (Baruch et al., 1999).  
CD36 contains 472 amino acids. The expected molecular mass is 53 kDa, 
however because of post translational protein modification, the apparent molecular 
mass is 78-88 kDa (Tang et al., 1994; Martin et al., 2007). Acylation occurs at residues 
1-6 and 461-472 of the intracellular domain and residues 7-28 and 439-460 of the 
trans-membrane domain. There are seven glycosylation sites (Hoosdally et al., 2009), 
a phosphorylation site (Lauzier et al., 2011) and disulphide bridges are present on 
extracellular domain (Rasmussen et al., 1998). There are also ubiquitination sites at 
residue Lys 469 and Lys 472 on the C-terminal (Smith et al., 2008).    
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Figure 1.1: Genomic distribution of CD36. It consist of 15 exons. Exons 1, 2 and 15 
are non-coding while exons 3 to 14 are coding regions. Exon 3 and exon 14 encodes 
for N- and C-terminal, respectively. 5’-untranslated region consists of exons 1, 2 and 
part of exon 3 while 3’-untranslated region consists of exons 14 and 15. This figure 
was adapted from Rac et al., 2007. 
 
Figure 1.2: Ligands for CD36 receptor. CD36 receptor domain bind to several ligands 
such as oxLDL and thrombospondin. Several protein post-translational modification 
sites including glycosylation also present on CD36 receptor domain. This figure was 
adapted from Lauzier et al., 2011 and Yamashita et al., 2007. 
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1.2.2 Function of CD36  
1.2.2(a) CD36 is involved in phagocytosis of pathogens and apoptotic cells  
 CD36 scavenger receptor function was first identified by Savil et al when he 
investigated the recognition of apoptotic cells by mononuclear phagocytes (Savill et 
al., 1991) which involved several receptor systems including CD36 in cooperation 
with αvβ3 integrin on the phagocyte surface (Savill et al., 1992).  
 CD36 uptakes and phagocytoses various bacterium including Escherichia coli, 
Klebsiella pneumoniae, Salmonella typhiurium, S. aureus and Enterococcus faecalis. 
CD36 is responsible in a TLR2/4 independent manner when induced by Gram-
negative bacteria and lipopolysaccharide (LPS) via a Jun N-terminal kinases (JNK)-
mediated signalling pathway (Baranova et al., 2008). 
1.2.2(b) CD36 as a fatty acid translocase (FAT) 
 Long chain fatty acid is a nutritional compound that serves various roles in the 
body. The main function of fatty acid is for cellular energy production, formation of 
phospholipids membrane and acts in selected transduction events such as during 
protein phosphorylation (Glatz and Luiken, 2015).   
Studies on fatty acid uptake into isolated adipocytes revealed the FAT to be the 
rat homologue of CD36. CD36 facilitates the fatty acid uptake in adipocytes (Abumrad 
et al., 1993; Pohl et al., 2005), heart and skeletal muscles and intestine (Drover et al., 
2008). CD36 that is overexpressed in skeletal muscles causes a decrease in circulating 
fatty acids and triacylglycerols, enhances fatty acid oxidation and decreases fat 
deposition (Ibrahimi et al., 1999; Koonen et al., 2005). Studies done in CD36 knock-
out mice showed reduction in fatty acid uptake rates in heart (-50 to -80%), skeletal 
muscle (-40 to -75%) and adipose tissue (-60 to -70%) (Coburn et al., 2000). 
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 At the extracellular site, CD36 promotes the partitioning of the fatty acids into 
the outer leaflet of the lipid bilayer. Then, fatty acids translocate from outer to the inner 
leaflet of the membrane without assistance from the membrane proteins (Pohl et al., 
2005; Hamilton, 2007).  
At the inner sites of the membrane, fatty acids bind to the cytoplasmic fatty 
acid binding protein (FABPc). CD36 provides a docking site for FABPc or for 
enzymes that act on fatty acids such as acyl-CoA synthetase. CD36 organises the fatty 
acids within specific membrane domains to make it readily available for transport. At 
the extracellular sites, CD36 interacts with FABPc to facilitate cellular fatty acid 
uptake. A study showed transfection of CD36 in a rat heart muscle cell line without 
FABPc does not increase the fatty acid uptake (Van Nieuwenhoven et al., 1998), 
suggesting that CD36 only functions in the presence of FABPc. 
1.2.2(c) CD36 is involved in regulation of angiogenesis 
 Tumor suppressor genes from hamster cells that have the ability to control the 
inhibition of angiogenesis were found to be similar to TSP-1. This raises the possibility 
that TSP-1 acts as a target molecule in restrainings tumor growth (Good et al., 1990). 
Further studies showed that CD36 in microvascular endothelial cells mediates the 
inhibition of angiogenesis in response to TSP-1. This demonstrated that endothelial 
CD36 may be essential for the inhibition of angiogenesis by TSP-1 (Dawson et al., 
1997). CD36 also mediates anti-angiogenic activity through TSP-2 by activating a 
specific signalling cascade that causes pro-angiogenic response (Silverstein and 
Febbraio, 2007).  
Histidine-rich glycoprotein (HRGP) binds with high affinity to TSP-1. HRGP 
co-localises with TSP-1 in the stroma of human breast cancer and masks the anti-
angiogenic epitope of TSP-1. Thus, it can modulate the anti-angiogenic effect of TSP-
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1 (Simantov et al., 2001). HRGP contains a CD36 homology domain and blocks the 
anti-angiogenic activities of TSP, thus promoting angiogenesis (Silverstein and 
Febbraio, 2007).  
The interactions between TSP-1 and CD36 exert an anti-angiogenic response. 
CD36 in endothelial cells (ECs) associates with non-receptor protein tyrosine kinase 
fyn, lyn and yes. Interaction of TSP-1 towards TSP-1 results to the recruitment of fyn 
to the CD36 membrane complex. This results in the activation of kinase and 
subsequent p38 mitogen-activated protein kinase (MAPK). Other than that, induction 
of EC apoptosis via caspase-3-like effector is also linked to the antiangiogenic activity 
of TSP-1 (Jimenez et al., 2000).  
1.2.2(d) CD36 is involved in inflammation 
 Since CD36 is highly expressed in several types of immune cells such as 
macrophages which are responsible for internalising a variety of particles, it also plays 
an important role in inflammatory responses to many of these ligands. The 
inflammatory responses results in the association of several type of diseases such as 
atherosclerosis, malaria, obesity, lung injury, brain injury, insulin resistance as well as 
stroke (Febbraio et al., 2001).  CD36 interacts with several type of receptors such as 
TLR to promote inflammatory responses as well as phagocytosis. This leads to the 
production of several pro-inflammatory cytokines by macrophages (Lee et al., 2012).  
 CD36 was first shown to interact with TLR2 and TLR6 heterodimers. The 
cooperation of CD36 with these TLR promote tumor necrosis factor (TNF) production 
and enhance immune responses. TLR2 is required for recognition of numerous bacteria 
components, fungi and protozoa (Hoebe et al., 2005). CD36, through TLR4 and TLR6 
mediates inflammatory response to oxLDL and amyloid-β fibrils. Macrophages which 
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have a deficiency of CD36 together with TLR4 and TLR6, are unable to promote 
inflammation against oxLDL and amyloid-β fibrils respectively (Stewart et al., 2010).    
  CD36 mediates phagocytosis and internalisation of plasmodium falciparum 
malaria-parasitised erythrocytes (PEs), which activates the TLRs. However, there are 
no secretion of cytokines from the primary macrophages in responses to TLR2. This 
indicate that CD36 cooperate with other TRLs to promote cytokine responses. 
Therefore, it can be concluded that the internalisation of PE by CD36 is not dependent 
on the TLR signalling and are non-inflammatory. However, internalisation of PE by 
CD36 can be enhanced by interactions with other TLRs to promote cytokine 
production (Erdman et al., 2009). The non-inflammatory response of PE 
internalisation by CD36 is more likely to resemble the uptake of apoptotic cells rather 
than bacteria. Thus, reducing the host inflammatory response can decelerate the PE 
clearance. 
1.3 Atherosclerosis 
Atherosclerosis is a worldwide disease where the fatty acid substances known 
as plaque builds up and accumulates inside the arteries and causes the arteries to 
become obstructed. Over time, the plaque which is made up of fat, cholesterol, calcium 
and other substances found in the blood, hardens and narrows the arteries. The 
blockage can restrict the blood flow and limit the flow of oxygen-rich blood to organs 
such as the heart, brain and other parts of the body. These events lead to serious 
cardiovascular diseases (CVD) such as coronary artery disease (CAD), coronary heart 
disease (CHD), peripheral arterial disease and cerebrovascular disease. 
1.3.1 Epidemiology of Atherosclerosis 
According to World Health Organisation (WHO), CVD remains the number 
one, non-communicable disease cause of death globally followed by cancer, 
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respiratory diseases and diabetes in year 2017. It was estimated that CVD caused 17.7 
million people to die in 2015 which represented 31% of all death globally. From this 
number, 7.4 million deaths were due to CHD and 6.7 million were due to stroke (World 
Health Organisation 2017).  
WHO also reported that, CAD caused the highest death rate in Ukraine and 
Russian Federation which was 718 and 654 deaths per 100 000 population respectively 
while the lowest death rate was in South Korea and Japan with 36.5 and 47.0 deaths 
per 100 000 respectively. Locally, based on the report of WHO, CAD caused 22, 158 
deaths in 2010 and the number increased to 24, 900 deaths in 2012 or about one fifth 
of all death. 498 deaths per 100 000 population were reported in 2015. This made CAD 
the most common cause of death as it contributed to 20.1% of all deaths (World Health 
Organisation 2017).  
National Cardiovascular Disease database (NCVD) reported that Malaysians 
obtained ACS at a young age mean between 55.9 to 59.1 years compared to developed 
countries where the mean age was between 63.4 to 68 years (Lu and Nordin, 2013). In 
2006 to 2010, it was found that among 13,591 ACS patients, 24.2% were women and 
had more risk factors and higher mortality (Lu et al., 2014).  
1.3.2 Risk factor of atherosclerosis 
 Risk factors of atherosclerosis are divided into two types which is life styles 
and health conditions. Having a lifestyle which included smoking (Yang et al., 2017), 
unhealthy diet (Fernstrom et al., 2017) and alcohol consumption (Patel et al., 2017) 
could result in atherosclerosis. Several conditions in the blood such as high cholesterol 
(Varbo and Nordestgaard, 2016), low density lipoprotein (LDL) (Lin et al., 2016), low 
level of high density lipoprotein (HDL) (Ahmed et al., 2016), insulin resistance 
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(Yamazoe et al., 2016), hyperglycemia (high blood sugar) (Tanaka et al., 2014), high 
blood pressure and obesity could also lead to atherosclerosis.  
There are also other risk factors such as sleep apnea, old age (Johnson et al., 
2017), hypertension (Korsager Larsen and Matchkov, 2016), and family history of 
heart disease (Khera and Kathiresan, 2017). In addition, there are several emerging 
risk factors that can cause atherosclerosis related diseases such as C-reactive protein 
(CRP), fibrinogen, and homocysteine (Hackam and Anand, 2003; Gupta et al., 2013).    
In Malaysia, WHO reported that 11.6% of adults have raised blood glucose, 
28.8% have raised blood pressure, 10.4% are obese and 43% of adult males are 
smokers. Data from National Health and Morbidity Survey (NHMS) stated that 32.7% 
were found to be hypertensive, 15.2% had diabetes and 35.1% had 
hypercholesterolemia among 18,231 adults at aged 18 years diagnosed in 2011 (World  
Health Organisation 2017).  
1.3.2(a) Life style 
Smoking has been reported to increase the incidence of CAD and myocardial 
infarction in male and female (Centers for Disease and Prevention, 2002). Cigarette 
smoke is associated with the reduction of nitric oxide (NO) availability which is 
primarily responsible for the vasodilatory function of the endothelium (Ota et al., 1997; 
Ambrose and Barua, 2004).  
Cigarette smoke also increases the level of several inflammatory markers 
including CRP, interleukin-6 (IL-6) and Tκα (Bermudez et al., 2002). It can also affect 
the lipid profile by elevating the serum cholesterol, triglyceride and LDL levels, and 
decreasing the HDL levels (Craig et al., 1989; Ambrose and Barua, 2004). Smoking 
increases the oxidation of LDL which is actively taken up by macrophages to form 
foam-cells (Heitzer et al., 1996; Ambrose and Barua, 2004). 
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The dietary components of a person are important to the development, 
prevention and treatment of cardiovascular diseases. Alternate Healthy Eating Index 
(AHEI) scores were associated with significant reductions of cardiovascular disease 
risk in men and women (McCullough et al., 2002). An unhealthy diet such as higher 
intake of fat, red meat and carbohydrate and less intake of fruits and vegetables would 
extend the coronary artery lesions in CAD patients.  
Practising a healthy life style such as not smoking, not consuming alcohol and 
consuming a balanced diet would prevent the majority of coronary diseases in women 
(Stampfer et al., 2000). Several physical activities such as walking, running or 
swimming would prevent the development of CAD and would reduce symptoms 
associated to the establishment of cardiovascular disease (Thompson, 2003). 
1.3.2(b) Cholesterol 
HDL, LDL, and several types of apolipoproteins such as apo A-1 and apo B 
are the dependent risk factors for atherosclerosis. Low levels of HDL and elevated 
levels of lipoprotein triglyceride contributed to the elevated cardiovascular risk 
(Chapman et al., 2011). Atherogenic lipoprotein are divided into three categories 
which are very low-density lipoprotein, LDL and intermediate-density lipoprotein 
(IDL). It is also sub-classified into phenotype A, large LDL particles, phenotype B, 
small LDL particles and intermediated phenotype (Austin et al., 1990; Carmena et al., 
2004). Oxidised LDL and small, dense LDL are more atherogenic compared to 
buoyant LDL particles.  
LDL particle size, which is smaller than 25.6 nm showed significant increase 
around 2.2 fold of ischemic heart disease compare to LDL particles which are larger 
than 25.6 nm in men (Lamarche et al., 2001). Apo B-100 is the major component of 
atherogenic lipoprotein and is used for estimating coronary risk. Since apo B is a 
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stronger risk predictor compared to LDL, apo B is more important marker in the 
diagnostic and treatment of patient with low levels of LDL (Walldius et al., 2001). 
1.3.2(c) Hyperglycemia 
 Hyperglycemia, condition where the blood glucose level is high, is the 
hallmark sign of diabetes type 1 and type 2. A normal person blood glucose level 
between 70-100 mg/dL. Clinical studies showed that hyperglycemia promotes 
cardiovascular events in type 2 diabetes (Brown et al., 2010; Mazzone, 2010). Once 
the glucose level increases, the body will produce insulin to trigger a response to 
inhibit the body from using fat for energy production.  
This results in the glucose from the bloodstream being used to make energy. 
However, insulin resistance can occur where the body fails to respond to the insulin 
which will result in higher levels of glucose in the blood. Clinical evidence have 
showed that insulin resistance promote CAD in the absence of hyperglycemia 
(DeFronzo, 2010) which suggests that insulin resistance is independent risk factor for 
atherosclerosis.  
1.3.2(d) Inflammation 
 Inflammation is the central aspect of atherosclerosis and it triggers the vascular 
events by mediating plaque instability. During inflammation, CRP is synthesised in 
the liver by stimulation of IL-6 and other pro-inflammatory cytokines (Libby, 2002). 
CRP is responsible for the prediction of events or mortality rate in patients with 
ischemic stroke (van Exel et al., 2002), acute coronary syndrome (Heeschen et al., 
2000) and peripheral vascular disease (Ridker et al., 2001).  
CRP expression is elevated in plaque and promotes the uptake of low-density 
lipoprotein by macrophages. It also up-regulates the intracellular adhesion molecule 
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by endothelial, thus promoting the recruitment of monocytes to plaque sites (Zwaka et 
al., 2001).  
1.3.3 Pathogenesis of atherosclerosis 
In atherosclerosis, the accumulation of oxLDL and apoliprotein B in the 
endothelial cellular layer leads to the recruitment of immune cells such as monocytes-
derived macrophages (Williams and Tabas, 1995; Moore and Tabas, 2011). 
Recruitment of oxLDL through CD36 triggers the signalling cascades for 
inflammatory responses (Park, 2014). Accumulation of T-cells and monocytes-derived 
macrophages forms foam cells loaded with lipids known as early fatty streak lesion.  
Lesion which consists of foam cell and necrotic core replaces the fibrous cap 
on the fibro atheromatous plaques (Yla-Herttuala et al., 2011). This leads to plaque 
rupture and formation of thrombus. Atherosclerosis is characterised by several events 
including activation and dysfunction of endothelial, inflammation of vascular, 
accumulation of modified lipid and formation of inflammatory cells in plaques form 
within vascular wall. 
1.3.3(a) Activation and dysfunction of endothelial 
Injured endothelial caused by exposure to metabolic or chemical stress 
including cigarettes smoke and diabetes mellitus lead to endothelial dysfunction. 
Plaque formations found at specific sites of endothelial results in endoplasmic 
reticulum stress which occurs with decreased athero-protective nitric oxide (NO) and 
increased superoxide production. Nitric acids produced by the endothelial nitric oxide 
synthase (NOS) are potentially atheroprotective and has vasolidator functions (Glass 
and Witztum, 2001). However, rapid interaction between NO and superoxide produces 
perovynitrite (ONOO-) that lead to the damage of proteins and lipids. Although 
peroxidase is needed as a signalling molecule in vascular, excess production is highly 
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pathological and linked to atherosclerosis This increase the endothelial permeability 
and lipid accumulation in sub-endothelial cells (Sima et al., 2009).  
The endothelial cells become activated in response to the oxLDL. LDL which 
is made up of phospholipids, is composed of fatty acids bound to a glycerol backbone 
with a polar head group, and is susceptible to free-radical enzymatic oxidation 
including reactive oxygen and nitrogen species. Enzymes present in vessel walls such 
as myeloperoxidase, lipoxygenase and other related enzymes generate reactive oxygen 
and nitrogen species (Hansson, 2001). One of the oxLDL receptor in endothelial 
dysfunction is lectin-type oxidised LDL receptor-1 (LOX-1). LOX-1 induces 
endothelial dysfunction by several mechanisms and induces pro-inflammatory 
cytokines (Xu et al., 2013). LOX-1 is highly expressed in endothelial dysfunction 
during early and advanced stages of atherosclerotic plaques. It is also expressed in 
smooth muscle cells and macrophages, suggesting that LOX-1 plays a role in 
endothelial activation and foam cell formation (Hansson, 2005).  
1.3.3(b) Leukocytes recruitment 
Endothelial activation causes induction of several cell surface adhesion 
molecules which mediates the attraction and attachment of leukocytes (monocytes and 
T cell). One of the adhesion molecules, monocyte chemo attractant protein-1 (MCP-
1) is a chemotactic protein for monocytes. The production of MCP-1 requires the 
activation of MAPK by oxLDL (Li and Mehta, 2000). MCP-1 potently attracts both 
monocytes and T-cell and plays vital role in recruitment of these cells.  
Activation of endothelial in response to oxLDL also up-regulates other 
chemokines including IL-8, which plays a role in monocytes-macrophages trafficking, 
chemokine (C-X-C) ligands 2 and 3 (Mattaliano et al., 2009). OxLDL also 
significantly increases E-selectin, P-selectin, vascular cell adhesion molecule-1 
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(VCAM-1) as well as intracellular adhesion molecules-1 (ICAM-1) expression which 
contributes to the recruitment of leukocytes to the atherosclerotic lesions (Hansson, 
2005). OxLDL also activates nuclear factor kappa B (NF-κB) which modulates 
expression of pro-inflammatory genes including cytokines, adhesion molecules and 
chemokines (Zhu et al., 2005). 
1.3.3(c) Macrophages CD36 mediates foam cell formation 
 Foam cell formation is the critical step of atherosclerosis. Within the intima, 
blood-circulating monocytes transmigrates into the arterial intima. At this site, 
monocytes differentiate into macrophages due to the presence of differentiation factors 
such as macrophage colony-stimulating factors (Sordet et al., 2002). At the early stage 
of atherosclerotic lesions, the majority of monocytes become cells with macrophages 
and/or dendritic cell-like structure features. Macrophages internalises the atherogenic 
lipoprotein, oxLDL via scavenger receptor CD36 (Park, 2014) and scavenger receptor-
A (SR-A) (Ricci et al., 2004). Oxidation of LDL promotes the specific ligands for 
nuclear hormone receptor PPAR-γ. This will up-regulate the expression of CD36 and 
further facilitate the uptake of oxLDL.  
Binding of macrophages to oxLDL via CD36 induces several transcriptional 
changes including up-regulation of CD36 expression. Following oxLDL uptake by 
macrophages via CD36, transcription factor PPARγ is transactivated via a p38 MAPK-
dependent pathway (Zhao et al., 2002). It also heterodimerises with retinoid X receptor 
(RXR). Interaction of RXR to PPAR response element in the CD36 promoter induces 
CD36 expression (Tontonoz et al., 1998). CD36 up-regulation mediated by oxLDL 
involves the initial activation of protein kinase C (PKC) (Feng et al., 2000) and protein 
kinase B (PKB) (Munteanu et al., 2006) dependent pathway with subsequent PPARγ 
activation.  
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Over-expression of PKB in macrophages is stimulated by CD36 promoter and 
PPARγ element-driven reporter gene. CD36 up-regulation by oxLDL is necessary for 
the differentiation of macrophages into foam cells (Rahaman et al., 2006). PPARγ also 
up-regulates CD36 expression in vascular smooth muscle cell (SMC) which is 
responsible for differentiation of SMC into foam cells (Lim et al., 2006). OxLDL 
stimulation cause the secretion of inflammatory cytokines including TNFα/β, IL-1β, 
IL-6 and interferon beta and gamma (IFNβ/γ) (Janabi et al., 2000). In addition, 
apoptosis occurs in macrophages and foam cells induced by oxLDL via a mechanism 
that is dependent on CD36 (Wintergerst et al., 2000). 
OxLDL activates eosinophils which up-regulates pro-inflammatory cytokines 
and down-regulates anti-inflammatory cytokines such as IL-4. Activation of 
eosinophils and CRP promotes pro-inflammatory M1 macrophages polarisation and 
down-regulation of M2 macrophages phenotype (Devaraj and Jialal, 2011). Activation 
of macrophages will secrete myeloperoxidase which oxidises more LDL, thus 
enlarging the pool of oxLDL (Carr et al., 2000). The interaction between CD36 and 
oxLDL induces secretion of several cytokines that causes infiltration of immune cell 
in the arterial intima (Jiang et al., 2012). This leads to foam cells formation and arterial 
inflammation which induces narrowing of arterial as shown in Figure 1.3.  
CD36 signalling cascade also activates NF-κβ, induces IL-1β and TNF-α 
(Yamashita et al., 2007). Internalisation of oxLDL via CD36 is mediated by a member 
of the small GTPase family, IRGM1 which is highly expressed by macrophages (Xia 
et al., 2013). Other receptors such as TLR 2 also enhances the CD36-mediated uptake 
of oxLDL (Erdman et al., 2009). 
Macrophages CD36 interact with oxLDL induce the phosphorylation of lyn 
and subsequently activate JNK 1 and 2. The uptake of oxLDL is mediated by JNK 
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activation (Rahaman et al., 2006) and the interaction also activates other MAPK such 
as p38 and ERK ½ (Zhao et al., 2002). CD36 signalling cascade is mediated by Vav, 
guanine nucleotide exchange factor. OxLDL induces the activation of macrophages by 
Vav. Inhibition of Vav-interacting protein, dynamin blocks the uptake of oxLDL 
(Rahaman et al., 2011).  
Several animal studies have shown that genetic deletion of CD36, which blocks 
the CD36 function in the signalling pathway, is able to reduce the atherosclerosis 
lesion formation. This can be seen in a study where in CD36-null mice, the uptake of 
oxLDL by macrophages are disrupted or defective (Febbraio et al., 2000). CD36-null 
mice including mice with ApoE null or LDL receptor null genotype showed less 
atherosclerotic lesion formation compared to ApoE null or LDL receptor null mice on 
high-fat diet (Guy et al., 2007; Kuchibhotla et al., 2008).  
 
Figure 1.3: Pathogenesis of atherosclerosis. Monocytes transmigrate from lumen into 
intima and causes endothelial cell dysfunction. Then, monocytes differentiate into 
macrophages and internalise oxLDL through CD36 receptor causing formation of 
foam cells. Vascular smooth muscle cells undergo apoptosis due to collagen 
degradation. This promotes plaque rupture and platelet aggregation. This figure was 
adapted from Park, 2014. 
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1.3.3(d) Plaque stabilisation and atherosclerotic lesion 
  In atherosclerosis, inflammation does not resolve spontaneously like acute 
inflammation which is resolved by the emigration of immune cells. Atherosclerotic 
inflammation causes macrophages to be trapped in the lesions. There are clear 
mechanism on how oxLDL is responsible for inhibition of macrophages emigration 
in-vitro and in-vivo (Park et al., 2009; Park et al., 2012). Macrophage cell polarity is 
one of the reasons of macrophage trapping. Macrophages loss its polarity due to 
activation of Vav/Rac pathway that is induced by oxLDL. This leads to the subsequent 
activation of non-muscle myosin II (Park et al., 2012).   
 Although the macrophages are trapped inside the lesion, they do not remain 
static due to the behaviour of different cell types including endothelial cells, SMC, 
macrophages as well as platelets. Plaques beneath the fibrous cap of extracellular 
matrix and vascular smooth muscle cells do not change the external arterial diameter, 
and this causes narrowing of the lumen. Plaque remain stable as long as the 
endothelium and fibrous cap are intact and become unstable once the cellular 
composition and structure rapidly change due to the presence of large lipid core and 
thin fibrous cap (Moore and Tabas, 2011).  
 Large lipid core is formed from due to macrophages being trapped inside the 
lesion. Fibrous cap becomes thin due to several cellular factors. Decrease of collagen 
synthesised by SMC contributes to the collagen degradation, and promotes plaque 
rupture. Macrophages triggers apoptosis by activating Fas apoptosis pathway, 
secretion of pro-apoptotic TNF-α and nitric oxide (Boyle et al., 2003).  
Macrophages secrete matrix metalloproteinases (MMPs) enzymes which 
degrade various type of extracellular matrix (ECM) proteins, thus contributing to the 
thin fibrous cap (Schneider et al., 2008).  There are also several macrophages-derived 
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serine protease such as cysteine protease that is responsible for degradation of elastin 
and collagen (Liu et al., 2004).  
 Plaque rupture leads to thrombus formation. Blood comes into contact with 
highly thrombogenic core and causes platelet aggregation. CD36 activates platelets to 
induce expression of P-selectin and activation of integrin α2bβ3 (Podrez et al., 2007). 
Platelet becomes hyperactive and activate signalling pathway that mediates 
oxLDL/CD36-induced platelet activation (Zimman et al., 2014). Rapid expansion of 
plaque and subsequent thrombus formation leads to acute coronary syndrome and 
myocardial infarction.  
1.3.4 Current treatments of atherosclerosis 
 Since there are a lot of risk factors that contributes to atherosclerosis, treatment 
of atherosclerosis includes several strategies such as lipid lowering drugs, anti-
inflammatory drugs, peptide vaccines and peptide inhibitor. Each strategy has its own 
advantages and disadvantages.  
1.3.4(a) Lipid lowering drug 
Recently, lipid lowering drugs such as statin successfully showed anti-
inflammatory property when delivered to atherosclerotic plaque using nanoparticle 
carrier, reconstituted high density lipoprotein (rHDL) (Duivenvoorden et al., 2014). 
Statin was able to provide primary and secondary prevention of atherosclerosis. 
However, several side effects of statin were identified including contribution to the 
coronary artery calcification and mitochondrial toxin accumulation that impaired 
muscle function in heart and blood vessels (Okuyama et al., 2015).  
1.3.4(b) Anti-inflammatory drug 
Several emerging therapeutic approaches were identified including Darapladib 
and methotrexate (MXT), and are both in clinical trial phase three. Darapladib is able 
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to significantly reduce major coronary artery events in stable coronary heart disease 
but not in acute coronary heart disease (O'Donoghue et al., 2014). MXT reduces intima 
media thickness (IMT) in patients with rheumatoid arthritis (RA) compared to the RA 
patient who did not receive MXT.  
1.3.4(c) Peptide vaccine 
Recently, several vaccination strategies in the form of peptide were established 
including apo B-100 peptide vaccine, heat shock protein (HSP) peptide vaccine and 
dendritic cells vaccine.  
Immunisation of atherosclerotic mice with major histocompatibility complex 
(MHC) class II restricted to 16 mer peptide derived from apo B-100 was able to 
significantly reduce atherosclerotic plaque and was able to induce CD4+ T regulatory 
cell, chemokine receptor 5 (CCR5) and secrete significant amounts of IL-10, 
suggesting the ability of this peptide to give atheroprotective effect against 
atherosclerosis (Kimura et al., 2017).   
Peptide derived from bacterial HSP 60 was used to immunise apo E deficient 
mice orally. HSP60 peptide was able to decrease lesion size, increase splenic T 
regulatory cell number and increase secretion of IL-10 mRNA levels in the aorta. This 
proved that HSP60 could be a potential candidate for vaccine development against 
atherosclerosis (Grundtman et al., 2015). 
Since dendritic cells (DC) is an antigen presenting cell, DCs were manipulated 
to provoke tolerance responses. Dendritic cells vaccine was achieved by loading the 
DC with specific antigen such as apo B-100 antigen, and transferred onto naive 
recipients. DC that had been pulsed with apo B-100 protein antigen were intravenously 
injected into low density lipoprotein deficient mice in combination with 
immunosuppresive cytokine, IL-10. DC-pulsed apo B-100 peptide was able to 
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significantly reduce 70% of  atherosclerotic lesion in aorta. It also inhibited the 
production of interferon-γ and decreased CD4+ T cell infiltration. Therefore, DC pulse 
apo B-100 peptide is a potential condidate to reduce autoimmune response against low 
density lipoprotein and in treatment of atheroslecrosis (Hermansson et al., 2011). 
1.3.4(d) Peptide inhibitor 
 Several peptide inhibitors for atherosclerosis were identified which inhibited 
specific proteins or receptors such as glucagon-like peptide (GLP-1), MMP, dipeptidyl 
peptidas-4 (DPP-4), apo B-100 and apo AI.  
GLP-1 such as exendin-4 and liraglutide significantly suppressed the oxLDL-
induced foam cell formation in human monocytes-derived macrophages while only 
liraglutide significantly retarded the atherosclerotic lesion and suppressed foam cell 
formation in macrophages of apolipoprotein E-deficient mice. (Tashiro et al., 2014). 
Liraglutide also inhibitfd the induction of vascular smooth muscle proliferation by 
activation of activated protein kinase (AMPK) signalling as well as inducing cell cycle 
arrest, thus delay the progression of atherosclerosis (Jojima et al., 2017). However, 
Thazhath showed a slightly different result as he reported that exendin-4 increased 
arterial blood pressure and heart rate of diabetes type 2 patients (Thazhath et al., 2017).        
MMP-9 and MMP-3 were expressed in atherosclerosis plaque of human 
patients undergoing peripheral revascularisation (Orbe et al., 2003). Less 
atherosclerotic burden was seen in double knockout mice which had deficiency in 
apolipoprotein and MMP-9 but not in MMP-12 knockout mice. This suggests that 
MMP-9 plays a major role in plaque growth (Luttun et al., 2004). Phosphinic peptide 
(RXP470.1) derived from murine MMP-12 inhbitor significantly reduced 
atherosclerotic plaque cross-sectional area by 50% in apolipoprotein E knockout mice. 
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This finding suggests that MMP-12 peptide inhibitor is able to delay athreosclerosis 
development (Johnson et al., 2011). 
DPP-4 inhibitor, Anagliptin is able to suppress the DPP-4 activity and increase 
the GLP-1 and GIP levels upon anagliptin treatment. Anagliptin also decreased the 
lesion formation in coronary arteries of Japanese white rabbits and reduced the 
expression of proinflammatory cytokines, tumor necrosis factor-alpha and interleukin-
6 in carotid arteries (Hirano et al., 2016).   
Several studies showed that Apo B-100 peptide antigen inhibits 
atherosclerosis. Fusion protein of B subunit of cholera toxin (CTB) with apoB-100 
peptide (p210) were used to immunise apoE deficient mice via nasal administration. 
After 12 weeks, aortic lesion size was reduced, regulatory T cells was induced to 
suppress effector T cells and number of interleukin 10 (IL-10) of CD4+ T cells was 
increased (Klingenberg et al., 2010). ApoB-100 derived peptide without adjuvant 
subcutaneuosly infused to the same animal model reduced plaque formation associated 
with vascular inflammation reduction and increased collagen. It also regulated cell 
response associated with the reduction of both T helper cell-1 and T helper cell-2 
(Herbin et al., 2012).   
 
1.3.5 Commercially available CD36 peptide 
Apart from the peptides used for treatment of atherosclerosis mentioned above, 
there are several commercialised CD36 peptides available. Synthetic CD36 blocking 
peptide such as CD36 blocking peptide from Abcam company, (domain 150-250 aa 
and 350-450 aa) (Abcam 2017) and from Cayman company (98-114aa) (Cayman 
Chemical 2017) , blocks the non-specific interaction of non-target antigen to the 
antibody epitope for molecular application such as western blot analysis, 
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immunohistochemistry, ELISA, flow cytometry and other antibody based 
applications. 
 Other CD36 peptides such as CD36 peptide P (93-110) and (139-155) were 
used as stimulator or inhibitor in CD36-TSP interactions. These peptides function in a 
two-step process of ligand receptor interaction. CD36 sequences of 139-155 represents 
a part of OMK5, monoclonal antibody-CD36 antibody epitopes. Application of P139-
155 enhances the binding of CD36 to TSP while P93-100 blocks binding of CD36 to 
TSP. However, in the presence of P139-155, P39-100 is able to bind to CD36 with 
higher affinity (Leung et al., 1992). 
 The identification of specific peptides against any molecule can be done by 
using phage display selection technique. By using this techniques, specific CD36 
peptide can be screened and identified. 
1.4 Phage display  
Phage display technology describes a selection technique by which a foreign 
polypeptide is fused to the capsid protein on lysogenic filamentous bacteriophages 
(Bazan et al., 2012a; Molek et al., 2011). Phage display is an extremely powerful tool 
for selection of peptides or proteins such as novel enzyme substrates and inhibitors 
(Skerra, 2007) and polypeptides with novel function and selection of new antibodies 
(Gronwall and Stahl, 2009).  
Phage display technology provides a physical linkage between phenotype (the 
displayed peptide) and genotype (the encoding DNA). During screening process, 
binding clones are separated from non-binding clones by affinity purification. Bio-
panning is the selection process by which the display library is incubated with an 
immobilised target, followed by an extensive washing to remove unspecific phages. 
Binders are eluted using acid, high salt or specific target ligand and enriched by 
